Filing Flows › U S Physical Therapy (USPH) › Stock forecast & fair value
U S Physical Therapy (USPH) stock forecast and fair value
U S Physical Therapy (USPH) trades at $86.44. 6 analysts' median price target is $98.00 (+13%), from $95.00 to $101.00. Across 28 valuation methods the middle fair value is $54.35 (-37%); the DCF says $44.69.
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| Regime-switching Monte Carlo 10th–90th | $9.65 | $48.72 | $133.98 | -44% |
| DCF — Monte Carlo 10th–90th percentile | $13.24 | $44.69 | $82.81 | -48% |
| P/E vs peers | $35.32 | $52.72 | $63.17 | -39% |
| P/E vs peers, weighted | $29.45 | $40.14 | $58.18 | -54% |
| P/E vs peers, matched | $34.85 | $54.35 | $64.41 | -37% |
| P/E vs peers, growth-adjusted | $33.69 | $47.93 | $68.18 | -45% |
| EV/EBITDA vs peers | $72.47 | $91.69 | $141.47 | +6% |
| EV/EBITDA vs peers, weighted | $47.00 | $83.20 | $98.90 | -4% |
| EV/EBITDA vs peers, matched | $69.40 | $83.28 | $129.51 | -4% |
| EV/EBITDA vs peers, growth-adjusted | $65.67 | $94.99 | $135.25 | +10% |
U S Physical Therapy's latest quarter
U S Physical Therapy, Q3 2026: revenue $223M (+13% year over year), operating margin 11.3%, net earnings $11.0M, operating cash flow $25.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for USPH stock?
The median of 6 analysts' 12-month targets is $98.00, +13% from $86.44; the range is $95.00 to $101.00. The average rating is buy.
What is U S Physical Therapy's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $23.92 and $163.41, with a middle value of $54.35 against a price of $86.44. Each method's assumptions are on the page.
Does U S Physical Therapy usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is USPH stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.